TY - JOUR AU - Gridelli, Cesare AU - Rossi, Antonio PY - 2012 TI - EURTAC first-line phase III randomized study in advanced non-small cell lung cancer: Erlotinib works also in European population JF - Journal of Thoracic Disease; Vol 4, No 2 (April 30, 2012): Journal of Thoracic Disease Y2 - 2012 KW - N2 - Activating epidermal growth factor receptor (EGFR) mutations represent the first target for which specific tyrosine kinase inhibitors (TKIs) are clinically available for the personalized treatment of advanced non-small cell lung cancer (NSCLC) patients. Until few months ago, three randomized phase III studies investigated the role of two EGFR-TKIs inhibitors, gefitinib (1-3) and erlotinib (4), as first-line treatment compared with standard platinum-based chemotherapy, in patients affected by advanced NSCLC harboring EGFR activating mutations. In all these trials the main endpoint was reached with EGFR-TKIs reporting a significant improvement in progression-free survival (PFS) and overall response rate (ORR). UR - https://jtd.amegroups.org/article/view/356